Loading company…
PRISM BioLab Co., Ltd. is a Japanese drug discovery company developing small molecules that modulate protein-protein interactions.
Established in 2006 and founded in Fujisawa, Japan, PRISM BioLab works on small molecule technologies that modulate protein-protein interactions. In July 2024 it listed on the Tokyo Stock Exchange Growth Section, selling 4 million shares at JPY 450 for JPY 1.8 billion and valuing the company at JPY 15.91 billion. Two clinical-stage assets for cancer and fibrosis have been licensed to Japanese pharma companies.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in